Prostate Cancer Coalition of New Hampshire

News You Can Use – August 2021

August 13, 2021 By PCCNH

mpMRI Misses Few Significant Prostate Cancers in Re-Biopsied Men

Obesity Linked to Lower Death Risk in mCRPC

EAU 2021: De Novo Versus Recurrent Metastatic mHSPC: What Is the Role of Modern Imaging?

EAU 2021: Phase 3 Study of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer (VISION)

EAU 2021: TheraP Phase 2 Trial of Lu-PSMA-617 vs Cabazitaxel: Results and Contrasts to the VISION Study

EAU 2021: Introduction and Setting the Stage: Prostate Cancer: cN+ in Newly Diagnosed Patients

EAU 2021: Monitoring and When To Change Treatment In mHSPC

EAU 2021: Tumor Molecular Testing: For Whom and When Is It Clinically Useful?

EAU 2021: PSMA In Diagnostics and Treatment

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.

The stanford prostate cancer calculator: Development and external validation of online nomograms incorporating PIRADS scores to predict clinically significant prostate cancer.

Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing.

Pathologic Outcomes in Prostate Cancer Cases Worsened During Pandemic

Apalutamide Prolongs Survival in mCSPC Regardless of Disease Volume

PSMA-PET/CT May Detect Prostate Cancer More Accurately Than mpMRI

Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.

Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.

The added value of PSMA PET/MR radiomics for prostate cancer staging.

MRI Can Avoid Unnecessary Prostate Biopsies Among Screened Men

Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.

Filed Under: News

News You Can Use – April 2021

April 4, 2021 By PCCNH

News & Information from Us Too

While we all must remain safe and socially distant due to COVID-19 restrictions, it is important for everyone to continue to monitor and address their health concerns, and stay connected to others. Us TOO has virtual prostate cancer support groups that continue to meet regularly and host guest speakers. These meetings can be accessed by phone or by internet, and can be attended from any location. For a list of groups, please visit:

ustoo.org/virtual-ustoo-support-groups

Us TOO offers virtual support for female caregivers of men with prostate cancer with A Forum for Her. For information on this group, visit ustoo.org/aforumforher. To join one of the Forum calls, or to volunteer to host a group for about an hour per month, please contact Terri Likowski at [email protected].

We also offer support for gay men and their partners with A Prostate Cancer Forum for Gay Men and Their Partners. For information on the group, visit ustoo.org/forumforgaymen. To join one of these calls, please contact Terri Likowski at [email protected].

AnCan offers a wide range of virtual support groups for men at every stage of prostate cancer. For more information, visit ancan.org/prostate-cancer.

The Reluctant Brotherhood hosts virtual meetings – “This call is for men living with cancer, any cancer at any stage. This is not a very technical call because we talk about what is going on inside our hearts and minds. We poke around with our emotional lives, the unmeasurable stuff.” For information, please visit thereluctantbrotherhood.org.

Virtual Support Groups

Us TOO has virtual prostate cancer support groups that continue to meet regularly and host guest speakers. These meetings can be accessed by phone or by internet, and can be attended from any location. For a list of groups, please visit: ustoo.org/virtual-ustoo-support-groups.

Webinars

We are excited to launch The Black Men’s Prostate Cancer Initiative to decrease health outcome disparities in prostate cancer treatment in the Black community through support and education. The initiative’s first community education webinar is a panel discussion on diet-related health disparities within the Black community and will feature an important conversation about nutrition and its impact on prostate, sexual, heart, and overall health. While this webinar series has been developed for the initiative’s pilot program, based in the Hyde Park area of Chicago, and will focus on information relevant to the Black community, the webinars are open to any interested parties. We look forward to you joining us on Thursday, March 25, 7:00 – 8:30pm Central. Register at: stoo.org/blackmenshealthwebinar.

Bone Health and Nutrition Webinar Video

On February 25th, we had a great kickoff to our 2021 webinar series, What is Right for Me in My Prostate Cancer Treatment? The first webinar was on the topic of Bone Health and Nutrition. We thank Gregory Lewis, MD, Christine M. Palumbo, RDN, FAND, and Jamie Kearns, MD for being a part of this valuable discussion. Thanks also to Amgen for their generous sponsorship of the webinar. Video of the webinar is available at ustoo.org/ustoo-video.

Filed Under: News

NH Governor Chris Sununu Proclaims September as Prostate Cancer Awareness Month

September 20, 2019 By PCCNH

Members of the Board of Directors for the NH Prostate Cancer Coalition meet with NH Governor Chris Sununu to receive a Proclamation declaring September as Prostate Cancer Awareness Month.

Left to right: Richard Hatin, Crissy Kantor, Governor Sununu, Julie Meyer, Anne Hatin and Harvey Keye.

Filed Under: News, Prostate Cancer

BREAKING NEWS: FDA Approves Apalutamide (Erleada) for the treatment of metastatic hormone-sensitive prostate cancer

September 18, 2019 By PCCNH

September 18, 2019 – Last night the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Apalutamide has previously received FDA-approval for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).

PCF funded the initial synthesis of apalutamide at UCLA by chemist Michael Jung, PhD, in collaboration with prostate cancer physician-scientist Charles Sawyers, MD (now at Memorial Sloan Kettering Cancer Center).

Read More

Filed Under: Events, News

Ben Stiller shares his Prostate Cancer journey in this powerful article

October 10, 2016 By PCCNH

1_4ahawxbpbfs7wrkwtk0u4q1

View The Story On Medium

Filed Under: News, Prostate Cancer

  • 1
  • 2
  • Next Page »
  • Home
  • About
  • PCCNH Officers and Directors
  • Sponsors & Partners
  • FAQ
  • Resources
  • One Man’s Story: A Conversation About Living With Prostate Cancer
  • Support Groups
New Hampshire Prostate Cancer Coalition believes that information about products and services that could benefit people with prostate cancer should be made available to all consumers so they may make informed decisions. Any references to specific products, services, organizations or claims made in any advertisements or sponsorships of New Hampshire Prostate Cancer Coalition does not constitute an endorsement or recommendation of that product or service. New Hampshire Prostate Cancer Coalition strongly urges you to consult with a qualified medical doctor when considering all options concerning prostate cancer treatment.

Awareness - Education - Support - Research 

© 2023 Prostate Cancer Coalition of New Hampshire · Website Services by Orchid Sun